Signaling lymphocytic activation molecules Slam and cancers: friends or foes? - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Oncotarget Année : 2018

Signaling lymphocytic activation molecules Slam and cancers: friends or foes?

Résumé

Signaling Lymphocytic Activation Molecules (SLAM) family receptors are initially described in immune cells. These receptors recruit both activating and inhibitory SH2 domain containing proteins through their Immunoreceptor Tyrosine based Switch Motifs (ITSMs). Accumulating evidence suggest that the members of this family are intimately involved in different physiological and pathophysiological events such as regulation of immune responses and entry pathways of certain viruses. Recently, other functions of SLAM, principally in the pathophysiology of neoplastic transformations have also been deciphered. These new findings may prompt SLAM to be considered as new tumor markers, diagnostic tools or potential therapeutic targets for controlling the tumor progression. In this review, we summarize the major observations describing the implications and features of SLAM in oncology and discuss the therapeutic potential attributed to these molecules.
Fichier principal
Vignette du fichier
24575-343823-5-PB.pdf (1.83 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

inserm-02455443 , version 1 (26-01-2020)

Identifiants

Citer

Gregory Fouquet, Ingrid Marcq, Véronique Debuysscher, Jagadeesh Bayry, Amrathlal Rabbind Singh, et al.. Signaling lymphocytic activation molecules Slam and cancers: friends or foes?. Oncotarget, 2018, 9 (22), pp.16248-16262. ⟨10.18632/oncotarget.24575⟩. ⟨inserm-02455443⟩
92 Consultations
187 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More